Jan. 11, 2019 - The collaboration is aimed at developing oral medications targeting the GDF11, or growth differentiation factor 11, pathway and associated targets — a concept that Elevian has been working on since inception.
Jan. 9, 2019 - Insilico will apply its generative adversarial networks and reinforcement learning technologies to biological and structural target data from Elevian to identify small molecules that produce the intended biological actions.
Oct. 24, 2018 - While we’re still far away from these fountain of youth treatments on drugstore shelves, we may be seeing the first wave of what could ultimately redefine the human experience.
Sept. 10, 2018 - In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. The funding was from Bold Capital, led by Peter Diamandis, Elevian’s founding investor, WTI, Stanford StartX, Longevity Fund, Kizoo Ventures, Thynk Capital and others.
Sept. 10, 2018 - Regenerative medicine company Elevian Inc. (Allston, Mass.) launched on Sept. 6 with $5.5 million in seed funding from Bold Capital, WTI, Stanford StartX fund, Longevity Fund, Kizoo Ventures, Thynk Capital and additional undisclosed investors.
Sept. 10, 2018 - Startup Elevian has raised millions to investigate whether a specific protein in young blood can have rejuvenating effects, despite disagreements over whether the science behind the idea is sound.
Sept. 10, 2018 - Elevian is developing medicines that restore the body's regenerative capacity, with the potential to treat and prevent age-related diseases. Elevian’s founders, working at Stanford and Harvard, discovered that young blood stimulates regeneration of many tissues and organs in old animals.
Sept. 7, 2018 - A startup in San Francisco called Elevian has rounded up $5.5 million in seed cash to pursue its work on a regenerative medicine program.
Sept. 7, 2018 - It’s an amazing idea, and it could represent a feedback loop where for every year of life gained, new technological advances will add another year. It’s really neat to think about.
Sept. 7, 2018 - New startup Elevian has launched with $5.5 million in backing to develop drugs based on GDF11, a Harvard University-discovered protein that it says is linked to age-related diseases.
Sept. 6, 2018 - Today, the latest young-blood medicine-maker, Elevian, emerged from stealth with $5.5 million from investors including Peter Diamandis, one of the more prominent faces in the Silicon Valley “death disruption” scene. Beneath all the hype is some striking science.
Sept. 6, 2018 - A series of eye-catching papers on parabiosis experiments in mice, which identified a circulating protein that reverses aging-related tissue degeneration, has led to the formation of a new Harvard University spin-out, Elevian Inc., which has just closed a seed round of $5.5 million.
Sept. 6, 2018 - A company co-founded by former physician Mark Allen and several Harvard researchers are trying to develop a therapeutic to address aging to treat diseases like heart failure, coronary artery disease, and muscular dysfunction.
Sept. 5, 2018 - Age is the No. 1 risk factor behind most diseases in the developed world, according to numerous studies. That’s why Elevian, led by a team of Harvard researchers, is working to develop medicine that treats aging by restoring the body’s regenerative capacities.
Jul. 15, 2017 - Might that be true for people, too?
Dec. 18, 2014 - In work with profound implications for aging, researchers showed that blood from a young mouse can rejuvenate an old mouse's muscles and brain.
May 4, 2014 - After combining the blood circulations of two mice by conjoining them — one old, the other young — researchers found dramatic improvements in the older mouse’s muscle and brain. After four weeks, stem cells in both those areas got a boost of activity and were better able to produce neurons and muscle tissue.